Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19645492 | 0.98 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261514 | 0.95 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19645487 | 0.94 | LMNA (0.61) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL24063887 | 0.93 | LMNA (0.51) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261485 | 0.92 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL20273214 | 0.92 | LMNA (0.49) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261519 | 0.91 | LMNA (0.54) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261530 | 0.90 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261524 | 0.90 | LMNA (0.53) | LMNACYP2C19HIF1A | |
| SCHEMBL19261523 | 0.90 | LMNA (0.74) | LMNACYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185598-B2 | Preparation of stabilised x-ray diagnostic composition | GE HEALTHCARE AS (NO) | 2021-11-30 | — | — | US | disclosed |
| US-9938233-B2 | Purification of X-ray contrast agents | GE HEALTHCARE AS (NO) | 2018-04-10 | — | — | US | disclosed |
| US-9884808-B2 | Preparation of an intermediate compound of ioforminol | GE HEALTHCARE AS (NO) | 2018-02-06 | — | — | US | disclosed |
| US-9827334-B2 | Preparation of ioforminol, an x-ray contrast agent | GE HEALTHCARE AS (NO) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185598-B2 | Preparation of stabilised x-ray diagnostic composition | HAX1, XPO5, IPO5 | LMNA 1438/4885CYP2C19 925/4885HIF1A 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.